Literature DB >> 2550560

Alpha-melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice.

L A Rheins1, A L Cotleur, R S Kleier, W B Hoppenjans, D N Saunder, J J Nordlund.   

Abstract

The neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) can act as an antagonist to interleukin 1 (IL-1) bioactivities such as inhibition of fever production, thymocyte proliferation, and inhibition of release of acute phase inflammatory molecules from the liver. In this report we have found that epicutaneous application of alpha-MSH suppresses both the sensitization and elicitation limbs of the cutaneous immune response (CIR) to potent contact sensitizers like dinitrofluorobenzene (DNFB) or oxazalone (OX) in mice. Further, the loss of contact hypersensitivity due to applications of alpha-MSH could be reconstituted by either intradermal or intravenous injections of epidermal thymocyte activating factor (ETAF)/interleukin-1. Topical application of alpha-MSH did not cause an alteration in Ia+ dendritic cells (i.e., Langerhans cells) but did produce a significant reduction in the expression of Thy1.2 marker on the Thyl+ dendritic epidermal cells (Thy1+DEC). It has no effects on the phenotypic expression of asialo GM-1 on these same cells. These observations suggest that alpha-MSH, a peptide classically isolated from the pituitary but found in many other tissues and cells of the body, may represent an additional biologic modifier than can modulate suppression of the contact hypersensitivity responses to various haptens. However, the mechanisms by which alpha-MSH or potentially other peptides found in the skin produce these suppressive effects have not been elucidated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550560     DOI: 10.1111/1523-1747.ep12284064

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Alpha-melanocyte stimulating hormone inhibits monocytes adhesion to vascular endothelium.

Authors:  Yang Yang; Weihua Zhang; Lin Meng; Haitao Yu; Na Lu; Gang Fu; Yang Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-20

2.  Active Cushing Disease Is Characterized by Increased Adipose Tissue Macrophage Presence.

Authors:  Irene T Lee; Alexandria Atuahene; Hale Ergin Egritag; Ling Wang; Michael Donovan; Christoph Buettner; Eliza B Geer
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

3.  Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes.

Authors:  E Schauer; F Trautinger; A Köck; A Schwarz; R Bhardwaj; M Simon; J C Ansel; T Schwarz; T A Luger
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

4.  Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone.

Authors:  R A Star; N Rajora; J Huang; R C Stock; A Catania; J M Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

5.  Melanotropin receptors demonstrated in situ in human melanoma.

Authors:  J B Tatro; M Atkins; J W Mier; S Hardarson; H Wolfe; T Smith; M L Entwistle; S Reichlin
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 6.  Proopiomelanocortin production by epidermal cells: evidence for an immune neuroendocrine network in the epidermis.

Authors:  R S Bhardwaj; T A Luger
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

7.  Proopiomelanocortin expression in the skin during induced hair growth in mice.

Authors:  A Slominski; R Paus; J Mazurkiewicz
Journal:  Experientia       Date:  1992-01-15

8.  Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model.

Authors:  D A C Botte; I L Noronha; D M A C Malheiros; T V Peixoto; S B V de Mello
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

9.  alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.

Authors:  Thomas A Luger; Thomas Brzoska
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.